News

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide.

Grenova and its division partners are backed by healthcare-focused private equity firm Peloton Equity.

Hull brings more than 30 years of leadership experience in the life sciences and diagnostics industries and has served on the Grenova Board of Directors for the past 13 months. He previously served as CEO of Bako Diagnostics and Genova Diagnostics – a former FFC company, Peloton’s predecessor firm – and has worked closely with Peloton Equity as an operating partner.

“Given the increasing demand for automation across laboratory workflows, this is a particularly exciting time to build a scaled, integrated platform in this space. Grenova, Peak Robotics, and PAA each bring world-class capabilities in their respective fields, creating a unique set of solutions for our customers,” said Ted Hull. “I’m incredibly excited to work alongside this team to shape the future of scientific automation.”

“We’re thrilled to partner with Ted again,” said Michael O’Rourke, Partner at Peloton Equity. “Ted brings a rare combination of operational leadership, industry expertise, and a deep understanding of how to scale growth companies. Having worked closely with the company and served alongside the leadership team, he is uniquely positioned to lead this next phase of growth.”

With the combined capabilities of Grenova’s technologies and the automation and integration expertise of Peak Robotics and PAA, the organization is positioned to deliver modular, scalable solutions and become a global leader in laboratory automation.

Read more here.

Recent News

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation

08/05/2026

Virginia Catalyst Announces Opening of Grant Round 20

The Virginia Catalyst announced that it is accepting letters of intent (LOI) for Grant Round 20 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The Virginia Catalyst is excited to open Grant Round 20 to continue our support of Virginia’s